Quantifying the impact of NSAID-associated adverse events.
Quantifying the impact of NSAID-associated adverse events.
复制标题
量化 NSAID 相关不良事件的影响。
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
M. Fine
中科院分区：
文献类型：
--
作者：
M. Fine
非甾体抗炎药 (NSAID) 广泛用于经历多种不同类型疼痛的患者，包括炎症、急性疼痛（例如受伤、腰痛、头痛、术后疼痛）和慢性疼痛（例如类风湿性关节炎、骨关节炎）。然而，传统的 NSAID 和第二代 NSAID（环氧合酶 2 抑制剂）都会导致非常昂贵且严重的不良事件。与非甾体抗炎药相关的胃肠道、心血管和肾脏并发症已被证明具有剂量依赖性。 2005年，为了帮助最大程度地降低这些风险，美国食品和药物管理局发布了一项公共卫生建议，指出“NSAIDs应在符合个体患者治疗目标的情况下，在最短的时间内以最低有效剂量给药。”本文回顾了与非甾体抗炎药相关的严重不良事件相关的过度临床和经济负担。
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used among patients experiencing many different types of pain, including inflammatory, acute pain (eg, injury, low back pain, headache, postoperative pain), and chronic pain (eg, rheumatoid arthritis, osteoarthritis). However, both traditional NSAIDs and second-generation NSAIDs (cyclooxygenase-2 inhibitors) can lead to very expensive and serious adverse events. Gastrointestinal, cardiovascular, and renal complications associated with NSAIDs have been shown to be dose-dependent. In 2005, to help minimize these risks, the US Food and Drug Administration issued a public health advisory stating that "NSAIDs should be administered at the lowest effective dose for the shortest duration consistent with individual patient treatment goals." This article reviews the undue clinical and economic burden associated with NSAID-related serious adverse events.